Cannabis Law Report
MARCH 18, 2022
Husch Blackwell has launched its Psychedelics and Emerging Therapie s team, an interdisciplinary, cross-office group of lawyers capable of addressing the challenges faced by innovators that seek to research, develop and commercialize novel therapies based on psychedelic drugs. By Steve Levine & Marshall Custer. March 18, 2022.
Project CBD
FEBRUARY 27, 2023
Instead, patients turn to a mix of whatever individual medications, therapies, and lifestyle changes (especially exercise) help ease symptoms and improve quality of life. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial.” 110,2 (2010): 604-10. Pain and therapy vol. PloS one vol.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
APRIL 8, 2022
as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. At 36, MAPS is now older than I was when I started MAPS at age 32.
Cannabis Law Report
DECEMBER 9, 2021
(the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has completed the manufacturing of its clinical grade supply (“cGMP”) of AP-188 (“ N , N -Dimethyltryptamine or DMT”) at Canadian manufacturer Dalton Pharma Services.
Cannabis Law Report
OCTOBER 9, 2021
The United States Food and Drug Administration, based on the success of these studies, has granted a “Breakthrough Therapy” designation for use of psilocybin to treat depression, meaning it demonstrates substantial improvement over available treatments. Subject: REVISED – Public Health Benefits of Psilocybin Act.
Cannabis Law Report
JANUARY 4, 2022
NYSE: AMAM), a position he previously held from 2010 through 2015. I am so very proud of all Anebulo has achieved over the past 18 months, including building out a highly effective team, securing new intellectual property protection, preparing and starting a proof-of-concept clinical trial, advancing regulatory discussions with the U.S.
Cannabis Law Report
JULY 6, 2021
He was also listed in “Best Doctors in America” in 2007, 2009, and 2010. Johnson, DSc, MD, MPhil, FRCPsych said, “I am pleased to join the Ehave Medical Advisory Board and look forward to working towards bringing psychedelic-assisted therapies to patients experiencing substance use issues. Johnson received the R.
Expert insights. Personalized for you.
52 
Let's personalize your content